These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 12182748)
1. Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. Netzer P; Schmitt B; Inauen W Aliment Pharmacol Ther; 2002 Aug; 16(8):1481-90. PubMed ID: 12182748 [TBL] [Abstract][Full Text] [Related]
2. The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients. Van Herwaarden MA; Samsom M; Van Nispen CH; Verlinden M; Smout AJ Aliment Pharmacol Ther; 2000 Apr; 14(4):453-62. PubMed ID: 10759625 [TBL] [Abstract][Full Text] [Related]
3. Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Verhagen MA; Samsom M; Maes B; Geypens BJ; Ghoos YF; Smout AJ Aliment Pharmacol Ther; 1997 Dec; 11(6):1077-86. PubMed ID: 9663833 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. Chen CL; Orr WC; Verlinden MH; Dettmer A; Brinkhoff H; Riff D; Schwartz S; Soloway RD; Krause R; Lanza F; Mack RJ Aliment Pharmacol Ther; 2002 Apr; 16(4):749-57. PubMed ID: 11929393 [TBL] [Abstract][Full Text] [Related]
5. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Talley NJ; Verlinden M; Geenen DJ; Hogan RB; Riff D; McCallum RW; Mack RJ Gut; 2001 Sep; 49(3):395-401. PubMed ID: 11511562 [TBL] [Abstract][Full Text] [Related]
6. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Talley NJ; Verlinden M; Snape W; Beker JA; Ducrotte P; Dettmer A; Brinkhoff H; Eaker E; Ohning G; Miner PB; Mathias JR; Fumagalli I; Staessen D; Mack RJ Aliment Pharmacol Ther; 2000 Dec; 14(12):1653-61. PubMed ID: 11121915 [TBL] [Abstract][Full Text] [Related]
7. Relationship between acceleration of gastric emptying and oesophageal acid exposure in patients with endoscopy-negative gastro-oesophageal reflux disease. Carmagnola S; Fraquelli M; Cantù P; Conte D; Penagini R Scand J Gastroenterol; 2006 Jul; 41(7):767-72. PubMed ID: 16785188 [TBL] [Abstract][Full Text] [Related]
8. Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease. Gardner JD; Rodriguez-Stanley S; Robinson M; Miner PB Aliment Pharmacol Ther; 2002 Oct; 16(10):1819-29. PubMed ID: 12269977 [TBL] [Abstract][Full Text] [Related]
9. Effects of a 5-HT(4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Tutuian R; Mainie I; Allan R; Hargreaves K; Agrawal A; Freeman J; Gale J; Castell DO Aliment Pharmacol Ther; 2006 Jul; 24(1):155-62. PubMed ID: 16803614 [TBL] [Abstract][Full Text] [Related]
11. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Kahrilas PJ; Quigley EM; Castell DO; Spechler SJ Aliment Pharmacol Ther; 2000 Nov; 14(11):1503-9. PubMed ID: 11069322 [TBL] [Abstract][Full Text] [Related]
12. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. van Herwaarden MA; Samsom M; Rydholm H; Smout AJ Aliment Pharmacol Ther; 2002 Sep; 16(9):1655-62. PubMed ID: 12197845 [TBL] [Abstract][Full Text] [Related]
13. Gastric emptying and duodeno-gastro-oesophageal reflux in gastro-oesophageal reflux disease. Freedman J; Grybäck P; Lindqvist M; Granström L; Lagergren J; Hellström PM; Jacobsson H; Näslund E Dig Liver Dis; 2002 Jul; 34(7):477-83. PubMed ID: 12236480 [TBL] [Abstract][Full Text] [Related]
14. The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial. Hobson R; Farmer AD; Dewit OE; O'Donnell M; Hacquoil K; Robertson D; Barton ME; Dukes GE Neurogastroenterol Motil; 2015 Nov; 27(11):1629-37. PubMed ID: 26348542 [TBL] [Abstract][Full Text] [Related]
15. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Ruth M; Finizia C; Cange L; Lundell L Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1115-21. PubMed ID: 14501621 [TBL] [Abstract][Full Text] [Related]
16. Impaired gallbladder and gastric motility and pathological gastro-oesophageal reflux in gallstone patients. Portincasa P; Di Ciaula A; Palmieri V; Velardi A; VanBerge-Henegouwen GP; Palasciano G Eur J Clin Invest; 1997 Aug; 27(8):653-61. PubMed ID: 9279528 [TBL] [Abstract][Full Text] [Related]
17. Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study. Pehlivanov N; Sarosiek I; Whitman R; Olyaee M; McCallum R Aliment Pharmacol Ther; 2002 Apr; 16(4):743-7. PubMed ID: 11929392 [TBL] [Abstract][Full Text] [Related]
18. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. McCallum RW; Cynshi O; Aliment Pharmacol Ther; 2007 Oct; 26(8):1121-30. PubMed ID: 17894654 [TBL] [Abstract][Full Text] [Related]